Drugs / Candida albicans antigen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02889159 | Jun 2016 → Feb 2023 | skin disorder | University of Michigan | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06720467 | Jun 2024 → Mar 2025 | viral eye infection | Zagazig University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03158168 | Mar 2018 → Jun 2019 | skin disorder caused by infection | Assiut University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06564805 | Aug 2024 → Jul 2025 overdue | alopecia areata | Autonomous University of Nuevo León | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Candida albicans antigen | “Intralesional injection of 0.2 ml of 1/1000 solution of Candida albicans antigen using an insulin syringe directly into the warts; Candida albicans 1:20 w/v 10 ml vial (Allergy...” NCT06720467 ↗ |
| Route | Other | “0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.” NCT02889159 ↗ |